EarningsVimian’s 3Q25 results came in ahead of expectations, with net revenue up 19%.
Financial PerformanceAdj. EBITA increased 17% year-over-year to EUR 25.5m, 5% above consensus.
Leadership And StrategyManagement emphasized continuity, sharper execution, and segment-level accountability, reaffirming confidence in Vimian’s long-term growth in the global animal health market.